VivoSeq
Other

Acute Lung Injury

38

Pipeline Programs↗

0

Active Trials↗

21

Companies Involved↗

Acute Lung Injury is a moderately active landscape with 38 programs across 21 companies. The most active players are Watson Pharmaceuticals, Amgen, GSK. 12 therapies are approved with 6 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

55/100

Pipeline Velocity

0/100

Mech. Concentration

12/100

Completion Rate

65/100

Attrition Rate

28/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

W

Watson Pharmaceuticals

1 program

Phase 1Amgen logo

Amgen

1 program

Phase 1GSK logo

GSK

2 programs

Phase 2Eli Lilly logo

Eli Lilly

2 programs

Phase 2S

S-Evans Biosciences Co., Ltd.

1 program

Phase 2Pfizer logo

Pfizer

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical3

Xenon

Nobilis Therapeutics Inc.

Simvastatin

Organon and Co

Ocotillol Type Ginsenoside Derivatives

The First Hospital of Jilin University

Phase 12

Sodium Nitroprusside

Watson Pharmaceuticals

VIB7734

Amgen

Phase 215

Dobutamine

Eli Lilly

Methylprednisolone

Pfizer

Norepinephrine

General Hospital of Ningxia Medical University

Aspirin

Bayer

CERC-002

Aevi Genomic Medicine, LLC, a Cerecor company

Phase 36

L-Citrulline

Asklepion Pharmaceuticals, LLC

Ravulizumab

AstraZeneca

Heparin

Baxter Healthcare Corporation

Plasmalyte a

Asklepion Pharmaceuticals, LLC

Calfactant

Grit Biotechnology

Approved12

Furosemide

Validus Pharmaceuticals

Dexmedetomidine

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Ivacaftor

Vertex Pharmaceuticals

Pirfenidone

Legacy Health System

Imatinib

Novartis

Analysis

Modality Breakdown

90%

Small molecule

38 of 42 classified programs — the dominant modality here.

10%ALL OTHERSCell therapy25%Monoclonal antibody12%Protein / enzyme12%

Small molecule leads; the ring shows all 42 classified programs, each share of the total. Modality classified for 100% of 43 pipeline programs.

Analysis

Trial Status

32

clinical trials

Completed17 · 53%
Terminated7 · 22%
Unknown status6 · 19%
Withdrawn2 · 6%

Clinical Trials

Trial Activity

32 trials

Role of Ascorbic Acid Infusion in Critically Ill Patients With Transfusion Related Acute Lung Injury
Completed·—·Phase 2·NCT04153487·40 enrolled
Mechanism of Delayed Neutrophil Apoptosis in Acute Lung Injury
Completed·TThe First Hospital of Jilin University·N/A·NCT04607434·40 enrolled
SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS
Completed·GSK logoGSK·Phase 2·NCT00996840·77 enrolled
Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury
Completed·AAevi Genomic Medicine, LLC, a Cerecor company·Phase 2·NCT04412057·88 enrolled
Vitamin C Infusion for Treatment in Sepsis Induced Acute Lung Injury
Completed·VVirginia Commonwealth University·Phase 2·NCT02106975·170 enrolled
L-citrulline for Prevention of Sequelae of Acute Lung Injury in Pediatrics Undergoing Cardiopulmonary Bypass for Heart Defects
Completed·AAsklepion Pharmaceuticals, LLC·Phase 3·NCT02891837·189 enrolled
A Phase II Randomized Trial of Fish Oil in Patients With Acute Lung Injury (ALI)
Completed·UUniversity of Washington·Phase 2·NCT00351533·90 enrolled
Hemodynamics and Extravascular Lung Water in Acute Lung Injury
Completed·OOregon Health and Science University·Phase 2·NCT00624650·33 enrolled
The Effect of Aspirin on REducing iNflammation in Human in Vivo Model of Acute Lung Injury
Completed·BBelfast Health and Social Care Trust·Phase 2·NCT01659307·33 enrolled
CALIPSO: Calfactant for Acute Lung Injury in Pediatric Stem Cell Transplant and Oncology Patients
Completed·MMilton S. Hershey Medical Center·Phase 2/3·NCT00999713·43 enrolled
Study in Intensive Care Patients to Investigate the Clinical Effect of Repetitive Orally Inhaled Doses of AP301 on Alveolar Liquid Clearance in Acute Lung Injury
Completed·AApeptico Forschung und Entwicklung GmbH·Phase 2·NCT01627613·40 enrolled
Nebulized Heparin for Prevention of Acute Lung Injury in Smoke Inhalation Injury
Completed·—·Phase 3·NCT05886998·88 enrolled
The Safety, Tolerability, PK and PD of GSK2586881 in Patients With Acute Lung Injury
Completed·GSK logoGSK·Phase 2·NCT01597635·44 enrolled
Sleep Intervention During Acute Lung Injury
Completed·UUniversity of Arizona·Phase 4·NCT01050699·90 enrolled
A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects With Acute Lung Injury
Completed·Eli Lilly logoEli Lilly·Phase 1/2·NCT00036062·600 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)